Previous 10 | Next 10 |
Nevro Announces Two Presentations from SENZA-PDN and SENZA-NSRBP Clinical Trials Have Been Accepted for Late-Breaking Abstract Sessions at NANS 2023 Annual Meeting PR Newswire SENZA-PDN 24-Month Follow-Up Results to be Presented on January 14, 2023 SENZA-NSRB...
Summary Nevro is a company that has developed a spinal cord stimulation implant to treat chronic pain. The FDA approved device is implanted into the back and has a good amount of clinical data to support the efficacy. Future growth relies on expanded geography, utilization, and the ...
Nevro Corporation (NVRO) Q3 2022 Earnings Conference Call November 02, 2022, 16:30 ET Company Participants Julie Dewey - Chief Corporate Communications & IR Officer Keith Grossman - Chairman, CEO & President Roderick MacLeod - CFO Conference Call Pa...
The following slide deck was published by Nevro Corp. in conjunction with their 2022 Q3 earnings call. For further details see: Nevro Corp. 2022 Q3 - Results - Earnings Call Presentation
Nevro press release ( NYSE: NVRO ): Q3 GAAP EPS of $2.22 beats by $2.32 . Revenue of $100.5M (+7.8% Y/Y) beats by $1.34M . Third Quarter 2022 Income from Operations of $82.1 Million, or Non-GAAP Loss from Operations of $22.9 Million Excluding Credits Related to...
Nevro Reports Third Quarter 2022 Financial Results, Narrows Full-Year 2022 Guidance and Raises Revenue Contribution from Painful Diabetic Neuropathy PR Newswire REDWOOD CITY, Calif. , Nov. 2, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), delive...
Nevro Corp. ( NYSE: NVRO ), a company focused on neuromodulation solutions, dropped at the open on Wednesday after its rival Boston Scientific ( BSX ) said that its Q3 sales for the pain treatment fell short of expectations. Boston Scientific’s ( BSX ) neuro...
The U.S. Food and Drug Administration (FDA) approved Nevro's ( NYSE: NVRO ) Senza HFX iQ spinal cord stimulation (SCS) system. Senza HFX iQ is the first and only Artificial Intelligence (AI)-based SCS system which learns from patients, the company said in an Oct. 12 pr...
Nevro Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain PR Newswire Next Generation Senza ® HFX iQ™ is the First and Only SCS System that Uses Artificial Intelligence to Optimize and M...
Healthcare equipment maker Nevro Corp. ( NYSE: NVRO ) announced Monday that the recent decision by UnitedHealthcare ( UNH ) to limit coverage for spinal cord stimulation (SCS) devices is unlikely to have a material impact on its future revenue. NVRO, the maker of the S...
News, Short Squeeze, Breakout and More Instantly...
Nevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024 PR Newswire REDWOOD CITY, Calif. , July 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-chan...
Nevro to Present at Truist Securities MedTech Conference PR Newswire REDWOOD CITY, Calif. , June 11 , 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chr...
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 PR Newswire REDWOOD CITY, Calif. , May 24, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the trea...